Aslan Pharmaceuticals announces publication on eblasakimab
The Fly

Aslan Pharmaceuticals announces publication on eblasakimab

ASLAN Pharmaceuticals announced the publication of data from the Phase 1a single ascending dose study of eblasakimab, a monoclonal antibody targeting the IL-13 receptor subunit of the Type 2 receptor, in Clinical Immunology, a bimonthly peer-reviewed journal, supporting eblasakimab’s potential as a novel, differentiated treatment for atopic dermatitis. The publication, titled “Eblasakimab, a novel IL-13 receptor alpha 1 monoclonal antibody, blocks STAT6 phosphorylation with low dose in human volunteers.” “We are excited about the publication of this data from our earlier Phase 1a study of eblasakimab in a high impact journal. The results show that eblasakimab appears to completely block IL-13Ralpha1 and inhibit activation of STAT6 which is responsible for driving expression of many inflammatory effector molecules,” said Dr Ferda Cevikbas, Head Translational Sciences, ASLAN Pharmaceuticals. “This, together with other data we have recently generated, suggests eblasakimab has the potential to be differentiated from other monoclonal antibodies acting on these pathways due to its distinct blocking of Type 2 receptor signaling without impairing Type 1 receptor signaling.”

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on ASLN:

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App